According to Agile Therapeutics
's latest financial reports the company has a price-to-book ratio of -0.2550.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | -0.3001 | -81.95% |
2022-12-31 | -1.66 | -110.99% |
2021-12-31 | 15.1 | 197.52% |
2020-12-31 | 5.09 | 33.34% |
2019-12-31 | 3.82 | 288.77% |
2018-12-31 | 0.9814 | -61.24% |
2017-12-31 | 2.53 | -34.68% |
2016-12-31 | 3.88 | -47.07% |
2015-12-31 | 7.32 | 130.44% |
2014-12-31 | 3.18 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.96 | -2,045.96% | ๐บ๐ธ USA |
Pfizer PFE | 1.73 | -779.40% | ๐บ๐ธ USA |
Merck MRK | 7.90 | -3,197.95% | ๐บ๐ธ USA |
TherapeuticsMD TXMD | 0.8851 | -447.09% | ๐บ๐ธ USA |